目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 SEGMENTS CONSIDERED & GEOGRAPHICAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key sources of secondary data
2.1.1.2 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key objectives of primary research
2.1.2.2 Key industry insights
2.1.2.3 Breakdown of primaries
2.2 MARKET SIZE ESTIMATION
2.2.1 REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH)
2.2.2 MNM REPOSITORY ANALYSIS
2.2.3 COMPANY INVESTOR PRESENTATIONS AND PRIMARY INTERVIEWS
2.2.4 TOP-DOWN APPROACH
2.3 MARKET GROWTH RATE PROJECTION
2.4 DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 DRUG DEVICE COMBINATION PRODUCTS MARKET OVERVIEW
4.2 ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION AND COUNTRY
4.3 DRUG DEVICE COMBINATION PRODUCTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of chronic diseases
5.2.1.2 Growing adoption of biologics and vaccines
5.2.1.3 High R&D investments from government organizations and private bodies
5.2.1.4 Shift toward personalized medicines and patient-centric care
5.2.1.5 Rising popularity of self-administered medicines
5.2.2 RESTRAINTS
5.2.2.1 Stringent regulatory policies and compliance hurdles
5.2.2.2 Focus on alternative drug delivery methods
5.2.3 OPPORTUNITIES
5.2.3.1 Increased preference for minimally invasive products
5.2.3.2 High growth potential in emerging economies
5.2.3.3 Growing adoption of drug device combination products and expanding biologics market
5.2.4 CHALLENGES
5.2.4.1 Heavy financial impact of drug wastage and device malfunction
5.2.4.2 Lack of standardized reimbursement policies
5.2.4.3 Limited training and education for healthcare professionals
5.2.4.4 Lack of medical specialists and surgeons
5.3 INDUSTRY TRENDS
5.3.1 RISING POPULARITY OF SELF-ADMINISTERED MEDICINES AND HOME CARE SETTINGS
5.3.2 INTEGRATION OF DRUG DEVICE COMBINATION PRODUCTS WITH SMART CONNECTED DEVICES
5.4 TECHNOLOGY ANALYSIS
5.4.1 KEY TECHNOLOGIES
5.4.1.1 Wearable technologies
5.4.1.2 Drug-eluting technologies
5.4.2 COMPLEMENTARY TECHNOLOGIES
5.4.2.1 Connected health and digital technologies
5.4.3 ADJACENT TECHNOLOGIES
5.4.3.1 Advanced materials and biopolymers
5.5 PORTER'S FIVE FORCES ANALYSIS
5.5.1 THREAT OF NEW ENTRANTS
5.5.2 THREAT OF SUBSTITUTES
5.5.3 BARGAINING POWER OF SUPPLIERS
5.5.4 BARGAINING POWER OF BUYERS
5.5.5 INTENSITY OF COMPETITIVE RIVALRY
5.6 KEY STAKEHOLDERS & BUYING CRITERIA
5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.6.2 KEY BUYING CRITERIA
5.7 REGULATORY ANALYSIS
5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7.2 REGULATORY FRAMEWORK
5.7.2.1 North America
5.7.2.1.1 US
5.7.2.1.2 Canada
5.7.2.2 Europe
5.7.2.3 Asia Pacific
5.7.2.3.1 India
5.7.2.3.2 China
5.7.2.3.3 Japan
5.7.2.4 Latin America
5.7.2.5 Middle East & Africa
5.8 PATENT ANALYSIS
5.8.1 KEY PATENTS GRANTED
5.9 TRADE ANALYSIS
5.9.1 TRADE ANALYSIS FOR PREFILLED SYRINGES (HS CODE 300431), 2019-2023
5.9.1.1 Import data for HS Code 300431
5.9.1.2 Export data for HS Code 300431
5.9.2 TRADE DATA FOR TRANSDERMAL PATCHES (HS CODE 300431), 2019-2023
5.9.2.1 Import data for HS Code 300431
5.9.2.2 Export data for HS Code 300431
5.10 PRICING ANALYSIS
5.10.1 INDICATIVE PRICING OF DRUG DEVICE COMBINATION PRODUCTS, BY KEY PLAYER, 2024
5.10.2 AVERAGE SELLING PRICE TREND OF INJECTABLE DRUG DELIVERY DEVICES, BY KEY PLAYER, 2022-2024
5.10.3 AVERAGE SELLING PRICE TREND OF DRUG DELIVERY COMBINATION PRODUCTS, BY REGION, 2022-2024
5.10.3.1 Average selling price trend for pen injectors, 2022-2024
5.10.3.2 Average selling price trend for inhalers, 2022-2024
5.10.3.3 Average selling price trend for drug-eluting stents, 2022-2024
5.11 VALUE CHAIN ANALYSIS
5.12 KEY CONFERENCES & EVENTS, 2025-2026
5.13 UNMET NEEDS/END-USER EXPECTATIONS
5.14 ADJACENT MARKET ANALYSIS
5.15 ECOSYSTEM ANALYSIS
5.15.1 ROLE IN ECOSYSTEM
5.16 CASE STUDY ANALYSIS
5.16.1 MINIMED 780G DIABETES MANAGEMENT SYSTEM TO COMBINE CONTINUOUS GLUCOSE MONITORING WITH AUTOMATED INSULIN DELIVERY
5.16.2 DIGIINHALER-SMART INHALER FOR ASTHMA/COPD TO TRACK LUNG FUNCTION
5.16.3 ADOPTION OF PEN INJECTORS BY NEMERA FRANCE TO IMPROVE THERAPEUTIC OUTCOMES
5.17 SUPPLY CHAIN ANALYSIS
5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.19 INVESTMENT & FUNDING SCENARIO
5.20 REIMBURSEMENT SCENARIO ANALYSIS
5.21 CLINICAL PIPELINE ANALYSIS
5.22 IMPACT OF AI/GEN AI ON DRUG DEVICE COMBINATION PRODUCTS MARKET
5.23 IMPACT OF 2025 US TARIFF ON DRUG DEVICE COMBINATION PRODUCTS MARKET
5.23.1 KEY TARIFF RATES
5.23.2 PRICE IMPACT ANALYSIS
5.23.3 IMPACT ON COUNTRY/REGION
5.23.3.1 North America
5.23.3.1.1 US
5.23.3.2 Europe
5.23.3.3 Asia Pacific
5.23.4 IMPACT ON END-USE INDUSTRIES
5.23.4.1 Hospitals & clinics
5.23.4.2 Ambulatory surgery centers
5.23.4.3 Long-term care facilities
5.23.4.4 Home care settings

6 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE
6.1 INTRODUCTION
6.2 INJECTABLE DRUG DELIVERY DEVICES
6.2.1 PREFILLED SYRINGES
6.2.1.1 Need to eliminate dosing mistakes and improve patient compliance to drive segment
6.2.2 PEN INJECTORS
6.2.2.1 Ease of self-administration and improved dosage accuracy to fuel adoption
6.2.3 AUTOINJECTORS
6.2.3.1 Ease of use and better patient experience to aid adoption in emergency medical conditions
6.2.4 WEARABLE INJECTORS
6.2.4.1 Rising popularity of embedded wireless devices to propel market growth
6.2.5 NEEDLE-FREE INJECTORS
6.2.5.1 Reduced risk of needlestick injury to fuel market adoption
6.3 DRUG-ELUTING STENTS
6.3.1 LOW RATE OF RESTENOSIS TO PROPEL MARKET GROWTH
6.4 INHALERS
6.4.1 INCREASING PREVALENCE OF RESPIRATORY DISEASES TO FUEL UPTAKE
6.5 INFUSION PUMPS
6.5.1 RISING NUMBER OF SURGICAL PROCEDURES TO FUEL DEMAND FOR AMBULATORY INFUSION PUMPS
6.6 TRANSDERMAL PATCHES
6.6.1 RISING INCIDENCE OF CHRONIC DISEASES REQUIRING LONG-TERM MEDICATION TO AID MARKET GROWTH
6.7 DRUG-COATED BALLOONS
6.7.1 ABILITY TO DELIVER LOCALIZED DRUG THERAPY WITH MINIMAL SYSTEMIC EXPOSURE TO DRIVE MARKET
6.8 OTHER PRODUCT TYPES

7 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 DIABETES MANAGEMENT
7.2.1 HIGH GERIATRIC POPULATION AND INCREASED SEDENTARY LIFESTYLE TO PROPEL MARKET GROWTH
7.3 RESPIRATORY DISEASES
7.3.1 RISE IN URBANIZATION, AIR POLLUTION, AND SMOKING TO FUEL RESPIRATORY AILMENTS
7.4 OPTHALMOLOGY
7.4.1 RISE OF DIABETIC EYE DISEASES AND FAVORABLE REGULATORY SCENARIO TO AUGMENT MARKET GROWTH
7.5 AUTOIMMUNE DISEASES
7.5.1 NEED FOR PROLONGED TREATMENT IN CHRONIC PATIENTS TO SPUR MARKET GROWTH
7.6 ONCOLOGY
7.6.1 DRUG DEVICE COMBINATION PRODUCTS TO AID THERAPEUTIC PRECISION AND OPTIMIZE PATIENT OUTCOMES DURING CANCER TREATMENT
7.7 INFECTIOUS DISEASES
7.7.1 IRREGULARIZED URBANIZATION AND POOR SANITATION IN EMERGING ECONOMIES TO PROPEL MARKET GROWTH
7.8 CARDIOVASCULAR DISEASES
7.8.1 INCREASE IN SEDENTARY LIFESTYLE AND CHANGES IN EATING HABITS TO FUEL MARKET GROWTH
7.9 OBESITY MANAGEMENT
7.9.1 INCREASING PREVALENCE OF OBESITY TO SUPPORT MARKET GROWTH
7.10 PAIN MANAGEMENT
7.10.1 BETTER PATIENT ADHERENCE AND MINIMAL SIDE EFFECTS TO DRIVE ADOPTION OF TRANSDERMAL PATCHES
7.11 OTHER APPLICATIONS

8 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOSPITALS & CLINICS
8.2.1 ACCESS TO MULTI-DISCIPLINARY EXPERTISE AND PROCEDURE-BASED CARE TO AID MARKET GROWTH
8.3 AMBULATORY SURGERY CENTERS
8.3.1 NEED FOR COST-EFFECTIVE AND HIGH-QUALITY MINIMALLY INVASIVE TREATMENT TO SUPPORT MARKET GROWTH
8.4 LONG-TERM CARE FACILITIES
8.4.1 INCREASING INCIDENCE OF CHRONIC DISEASES AMONG ELDERLY AND DISABLED POPULATION TO DRIVE MARKET
8.5 HOME CARE SETTINGS
8.5.1 INCREASING DEMAND FOR PATIENT-CENTRIC AND COST-EFFECTIVE HEALTHCARE TO PROPEL MARKET GROWTH
8.6 OTHER END USERS

9 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
9.2.2 US
9.2.2.1 US to dominate North American drug device combination products market during forecast period
9.2.3 CANADA
9.2.3.1 Regulatory modernization and strategic government investments to augment market growth
9.3 EUROPE
9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
9.3.2 GERMANY
9.3.2.1 Technological advancements and strong R&D infrastructure to propel market growth
9.3.3 UK
9.3.3.1 Strong emphasis on personalized and value-based healthcare to aid market growth
9.3.4 FRANCE
9.3.4.1 Strong healthcare infrastructure and high investments in biopharmaceutical innovation to boost market growth
9.3.5 ITALY
9.3.5.1 Focus on pharmaceutical-meditech convergence and healthcare modernization to drive market
9.3.6 SPAIN
9.3.6.1 Increasing geriatric population and growing focus on home-based treatment to propel market growth
9.3.7 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
9.4.2 CHINA
9.4.2.1 Favorable government policies and increased healthcare spending to support market growth
9.4.3 JAPAN
9.4.3.1 Advanced healthcare systems and universal reimbursement policies to spur market growth
9.4.4 INDIA
9.4.4.1 Growing focus on digital health integration and booming biosimilars sector to drive market
9.4.5 SOUTH KOREA
9.4.5.1 Robust R&D infrastructure and enhanced focus on government-industry collaborations to aid market growth
9.4.6 AUSTRALIA
9.4.6.1 Rising healthcare investments by government and private organizations to boost market growth
9.4.7 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
9.5.2 BRAZIL
9.5.2.1 Presence of universal healthcare system and high geriatric population to drive market
9.5.3 MEXICO
9.5.3.1 Focus on nearshoring and improvement in healthcare sector to drive market
9.5.4 REST OF LATIN AMERICA
9.6 MIDDLE EAST & AFRICA
9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
9.6.2 GCC COUNTRIES
9.6.2.1 Kingdom of Saudi Arabia
9.6.2.1.1 Developed medical tourism and favorable government initiatives to support market growth
9.6.2.2 UAE
9.6.2.2.1 Increased prevalence of diabetes and focus on innovative patient-centric care to drive market
9.6.2.3 Rest of GCC countries
9.6.3 REST OF MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DEVICE COMBINATION PRODUCTS MARKET
10.3 REVENUE ANALYSIS, 2020-2024
10.4 MARKET SHARE ANALYSIS, 2024
10.4.1 RANKING OF KEY MARKET PLAYERS
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
10.5.5.1 Company footprint
10.5.5.2 Region footprint
10.5.5.3 Product type footprint
10.5.5.4 Application footprint
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
10.6.1 PROGRESSIVE COMPANIES
10.6.2 RESPONSIVE COMPANIES
10.6.3 DYNAMIC COMPANIES
10.6.4 STARTING BLOCKS
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
10.6.5.1 Detailed list of key startups/SME players
10.6.5.2 Competitive benchmarking of key startups/SME players
10.7 COMPANY VALUATION & FINANCIAL METRICS
10.7.1 FINANCIAL METRICS
10.7.2 COMPANY VALUATION
10.8 BRAND/PRODUCT COMPARISON
10.9 COMPETITIVE SCENARIO
10.9.1 PRODUCT LAUNCHES AND APPROVALS
10.9.2 DEALS
10.9.3 EXPANSIONS
10.9.4 OTHER DEVELOPMENTS

11 COMPANY PROFILES
11.1 KEY PLAYERS
11.1.1 ABBOTT
11.1.1.1 Business overview
11.1.1.2 Products offered
11.1.1.3 Recent developments
11.1.1.3.1 Product launches and approvals
11.1.1.3.2 Deals
11.1.1.4 MnM view
11.1.1.4.1 Right to win
11.1.1.4.2 Strategic choices
11.1.1.4.3 Weaknesses & competitive threats
11.1.2 ELI LILLY AND COMPANY
11.1.2.1 Business overview
11.1.2.2 Products offered
11.1.2.3 Recent developments
11.1.2.3.1 Product approvals
11.1.2.3.2 Deals
11.1.2.3.3 Expansions
11.1.2.3.4 Other developments
11.1.2.4 MnM view
11.1.2.4.1 Right to win
11.1.2.4.2 Strategic choices
11.1.2.4.3 Weaknesses & competitive threats
11.1.3 MEDTRONIC
11.1.3.1 Business overview
11.1.3.2 Products offered
11.1.3.3 Recent developments
11.1.3.3.1 Product launches and approvals
11.1.3.3.2 Deals
11.1.3.4 MnM view
11.1.3.4.1 Right to win
11.1.3.4.2 Strategic choices
11.1.3.4.3 Weaknesses & competitive threats
11.1.4 NOVO NORDISK A/S
11.1.4.1 Business overview
11.1.4.2 Products offered
11.1.4.3 Recent developments
11.1.4.3.1 Product launches and approvals
11.1.4.3.2 Deals
11.1.4.3.3 Expansions
11.1.4.4 MnM view
11.1.4.4.1 Right to win
11.1.4.4.2 Strategic choices
11.1.4.4.3 Weaknesses & competitive threats
11.1.5 NOVARTIS AG
11.1.5.1 Business overview
11.1.5.2 Products offered
11.1.5.3 Recent developments
11.1.5.3.1 Product approvals
11.1.5.3.2 Deals
11.1.5.3.3 Expansions
11.1.5.4 MnM view
11.1.5.4.1 Right to win
11.1.5.4.2 Strategic choices
11.1.5.4.3 Weaknesses & competitive threats
11.1.6 SANOFI
11.1.6.1 Business overview
11.1.6.2 Products offered
11.1.6.3 Recent developments
11.1.6.3.1 Product approvals
11.1.6.3.2 Deals
11.1.6.3.3 Other developments
11.1.7 BOSTON SCIENTIFIC CORPORATION
11.1.7.1 Business overview
11.1.7.2 Products offered
11.1.7.3 Recent developments
11.1.7.3.1 Product approvals
11.1.7.3.2 Deals
11.1.8 BECTON, DICKINSON AND COMPANY
11.1.8.1 Business overview
11.1.8.2 Products offered
11.1.8.3 Recent developments
11.1.8.3.1 Deals
11.1.8.3.2 Other developments
11.1.9 MERCK KGAA
11.1.9.1 Business overview
11.1.9.2 Products offered
11.1.9.3 Recent developments
11.1.9.3.1 Deals
11.1.10 ABBVIE INC.
11.1.10.1 Business overview
11.1.10.2 Products offered
11.1.10.3 Recent developments
11.1.10.3.1 Product approvals
11.1.10.3.2 Deals
11.1.10.3.3 Expansions
11.1.11 TEVA PHARMACEUTICAL INDUSTRIES LTD.
11.1.11.1 Business overview
11.1.11.2 Products offered
11.1.11.3 Recent developments
11.1.11.3.1 Product approvals
11.1.11.3.2 Other developments
11.1.12 STRYKER
11.1.12.1 Business overview
11.1.12.2 Products offered
11.1.13 B. BRAUN SE
11.1.13.1 Business overview
11.1.13.2 Products offered
11.1.14 TERUMO CORPORATION
11.1.14.1 Business overview
11.1.14.2 Products offered
11.1.14.3 Recent developments
11.1.14.3.1 Product launches and approvals
11.2 OTHER PLAYERS
11.2.1 TANDEM DIABETES CARE, INC.
11.2.2 CEQUR SIMPLICITY
11.2.3 INTARCIA THERAPEUTICS, INC.
11.2.4 HALOZYME, INC.
11.2.5 KALEO, INC.
11.2.6 LEAD CHEMICAL CO., LTD.
11.2.7 PURDUE PHARMA L.P.
11.2.8 ALVOGEN
11.2.9 EVOLUTIS
11.2.10 MUNDIPHARMA INTERNATIONAL LIMITED
11.2.11 SPARSHA PHARMA INTERNATIONAL PVT. LTD.
11.2.12 SUPERNUS PHARMACEUTICALS, INC.
11.2.13 ALCON INC.

12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS